Why Is Chemed (CHE) Up 9.3% Since Last Earnings Report?

Chemed (CHE) reported Q2 2025 adjusted EPS of $4.27, missing estimates by 10.67% and declining 21.9% year-over-year, despite a 3.8% revenue increase that slightly topped forecasts. The company subsequently lowered its full-year 2025 adjusted EPS guidance to $22.00-$22.30, a significant reduction from previous estimates, and revised down VITAS revenue growth projections. This negative outlook has prompted a 5.56% downward shift in consensus estimates, leading to a Zacks Rank #5 (Strong Sell) for CHE, even as its shares have gained 9.3% since the earnings report.

Analysis

Chemed Corporation (CHE) presents a significant disconnect between its recent stock performance and underlying fundamental health. The company's shares rallied 9.3% in the month following its Q2 2025 earnings report, yet the results themselves were decidedly negative. Chemed missed adjusted EPS estimates by a substantial 10.67%, with the $4.27 figure representing a 21.9% decline year-over-year. While revenues saw a modest 3.8% increase, slightly beating consensus, this top-line growth did not translate to profitability. More critically, management issued a severe downward revision to its full-year 2025 guidance, cutting the adjusted EPS forecast from a midpoint of $25.20 to $22.15 and lowering the revenue growth outlook for its key VITAS segment. This negative outlook has triggered a 5.56% downward revision in analyst consensus estimates and earned the stock a Zacks Rank #5 (Strong Sell), indicating expectations of below-average returns. The stock's factor scores further highlight this dichotomy, with a strong 'A' for Growth but a weak 'D' for Value, suggesting the recent price appreciation is not supported by valuation metrics.

Key Decisions for Investors

• Investors should exercise extreme caution, as the 9.3% share price increase is directly contradicted by a significant earnings miss, a sharply reduced full-year guidance, and deteriorating analyst sentiment.
• The downward revision of the VITAS segment's revenue forecast is a material concern, and positions should be monitored closely for any further signs of weakness in this core business driver.
• Given the Zacks Rank #5 (Strong Sell) and the clear fundamental headwinds, the recent stock rally could represent a selling or shorting opportunity rather than a sustainable recovery, warranting a re-evaluation of any long positions.